In a recent transaction, Benjamin Jackson, the General Counsel of Sera Prognostics, Inc. (NASDAQ:SERA), sold 4,902 shares of the company's Class A Common Stock. This sale, which took place on May 8, 2024, amounted to over $47,000. The shares were sold at an average price of $9.59, with individual transactions occurring within a price range of $9.14 to $10.55.
The sale by Jackson was part of a "sell to cover" transaction, which is a common method for handling tax withholding obligations upon the vesting of restricted stock units (RSUs). This type of transaction is typically mandated by the company's policies to satisfy tax withholdings and is not necessarily indicative of the executive's discretionary trading intentions.
Following the sale, Jackson still holds a substantial number of shares in the company, amounting to 145,277 shares of Sera Prognostics' Class A Common Stock. This indicates a continued investment in the company's future by the General Counsel.
The price per share and the range of the block trade were provided by the reporting person, who has also committed to offering detailed information regarding the number of shares sold at each price point upon request by the Securities and Exchange Commission, the issuer, or any security holder of the issuer.
Sera Prognostics, based in Salt Lake City, Utah, specializes in medical laboratory services and is known for its work in the field of prognostics for pregnant women. As of now, there have been no further transactions reported by the company's executives or significant shareholders.
InvestingPro Insights
Amidst the news of the recent insider sale of Sera Prognostics shares by General Counsel Benjamin Jackson, investors and market watchers have been closely monitoring the company's financial health and stock performance. Sera Prognostics, Inc. (NASDAQ:SERA), which holds a market capitalization of approximately $302.25 million, has seen its stock face volatility, with a significant price total return of 181.32% over the last year. Nonetheless, the company has been trading at a high revenue valuation multiple, which is a point of consideration for potential investors.
An analysis of Sera Prognostics' financial data reveals a negative adjusted P/E ratio of -8.52 for the last twelve months as of Q1 2024. This metric suggests that the company is not currently profitable, a sentiment echoed by analysts who do not anticipate profitability for the year. Moreover, the company's revenue declined by 37.58% over the same period, with a gross profit margin of 19.9%.
Despite the recent downturn in share price over the past week, with a 1-week price total return of -9.77%, Sera Prognostics has experienced a strong return over the last three months, at 15.31%. The company also holds more cash than debt on its balance sheet, which may provide some financial stability in the short term. Additionally, its liquid assets exceed short-term obligations, an InvestingPro Tip that suggests the company has a cushion to cover immediate liabilities.
For those interested in a deeper dive into Sera Prognostics' financials and stock performance, there are additional InvestingPro Tips available. The platform currently lists 9 more tips that could provide investors with a more nuanced understanding of the company's position and potential future performance. To explore these insights, visit https://www.investing.com/pro/SERA, and don't forget to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.